- Home
- CMC vs TFX Comparison
CMC vs TFX Comparison
Compare CMC & TFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMC
- TFX
- Stock Information
- Founded
- CMC 1915
- TFX 1943
- Country
- CMC United States
- TFX United States
- Employees
- CMC N/A
- TFX N/A
- Industry
- CMC Steel/Iron Ore
- TFX Medical/Dental Instruments
- Sector
- CMC Industrials
- TFX Health Care
- Exchange
- CMC Nasdaq
- TFX Nasdaq
- Market Cap
- CMC 4.9B
- TFX 5.9B
- IPO Year
- CMC 1987
- TFX N/A
- Fundamental
- Price
- CMC $46.11
- TFX $125.15
- Analyst Decision
- CMC Buy
- TFX Hold
- Analyst Count
- CMC 7
- TFX 10
- Target Price
- CMC $60.33
- TFX $176.50
- AVG Volume (30 Days)
- CMC 805.3K
- TFX 690.7K
- Earning Date
- CMC 06-20-2025
- TFX 05-01-2025
- Dividend Yield
- CMC 1.56%
- TFX 1.08%
- EPS Growth
- CMC N/A
- TFX N/A
- EPS
- CMC 0.63
- TFX 3.20
- Revenue
- CMC $7,738,612,000.00
- TFX $3,010,144,000.00
- Revenue This Year
- CMC N/A
- TFX $1.40
- Revenue Next Year
- CMC $8.41
- TFX $4.85
- P/E Ratio
- CMC $73.02
- TFX $39.19
- Revenue Growth
- CMC N/A
- TFX 0.29
- 52 Week Low
- CMC $37.92
- TFX $121.70
- 52 Week High
- CMC $64.53
- TFX $249.91
- Technical
- Relative Strength Index (RSI)
- CMC 57.28
- TFX 40.95
- Support Level
- CMC $44.67
- TFX $120.06
- Resistance Level
- CMC $46.61
- TFX $138.93
- Average True Range (ATR)
- CMC 1.23
- TFX 3.82
- MACD
- CMC 0.38
- TFX -0.34
- Stochastic Oscillator
- CMC 83.84
- TFX 26.97
About CMC Commercial Metals Company
Commercial Metals Co operates steel mills, steel fabrication plants, and metal recycling facilities in the United States and manufactures rebar and structural steel, which are key product categories for the nonresidential construction sector. The Company has three operating and reportable segments: North America Steel Group, Europe Steel Group and Emerging Businesses Group.
About TFX Teleflex Incorporated
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.